Kolltan Pharmaceuticals
Kolltan develops and commercializes antibody-based drugs targeting Receptor Tyrosine Kinases for the treatment of cancer.
Business Model:
Revenue: $10M
Employees: 11-50
Rankings
Industries / Tags:
Detailed Kolltan Pharmaceuticals Information
Kolltan Pharmaceuticals was acquired by
Celldex Therapeutics.
The acquisition happend on 2016-11-01.
Details of the transaction were not public
Acquirer
Geographic Data
Address: 300 George St
City: New Haven
State: CT
Zip: 06511
Country: US
Financial Info
Stage:
series d
Raised Last:
$60M
Raised Total:$91M
Social
Metrics
0Website Global Rank
0Website Monthly Traffic
Twitter Followers
Description
Kolltan develops and commercializes antibody-based drugs targeting Receptor Tyrosine Kinases for the treatment of cancer.
Contact Phone:
+12037733000
Contact Email:
Kolltan Pharmaceuticals went public on the NASDAQ
Listed Exchange:
NASDAQ
Ticker Symbol:
KLTN
Live
Opened: -/share
| EBITDA | - |
| Total Cash | - |
| Total Debt | - |
| Total Revenue | - |
| Total Profit (Gross) | - |
| PE Ratio | - |
| Announced Date | Company | Transaction | Money Raised |
|---|
| Announced Date | Name | Price |
|---|
Employee Departments
Employee States
|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|
